Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported revenue ahead of Wall Street’s expectations in Q2 CY2025, ...

"The absence of a statistically significant benefit of adjuvant chemotherapy in the ASTER 70s trial underlines the persistent ...

Patients with psoriasis have significantly more difficulty sleeping, particularly in new environments, than matched ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...

Stock to Watch: Incyte (INCY) Wilmington, DE-based Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics.

Q2 2025 Earnings Call Transcript July 29, 2025 Incyte Corporation beats earnings expectations. Reported EPS is $2.04, expectations were $1.39. Operator: Greetings, and welcome to the Incyte Second ...

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with ...

Contract dispute settlement In May 2025, Incyte and Novartis entered into a settlement agreement with respect to litigation relating to the duration of royalty payments owed under the Collaboration ...

Incyte swung to a second-quarter profit on a sharp increase in revenue, and the company boosted 2025 sales projections for its cancer drugs. The maker of cancer drugs and other pharmaceuticals ...

Incyte (Nasdaq:INCY) today reports 2025 second quarter financial results, and provides a status update on the Company’s clinical development portfolio. "As I begin my tenure as ...